Sam Chun Dang Pharm. Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Sam Chun Dang Pharm. Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Sam Chun Dang Pharm.'s Price has grown, increasing from ₩0.00 to ₩0.00 – a growth of 100.00%. The next year looks promising for Sam Chun Dang Pharm., with analysts predicting Fair Value of ₩0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Sam Chun Dang Pharm.'s Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A128940 Stock Forecast | Hanmi Pharm. | Outperform |
18
|
₩310.50k | Buy/Sell | ₩382.71k | 33.66% |
| A008930 Stock Forecast | Hanmi Science | - |
14
|
₩42.55k | Buy/Sell | ₩0.00 | -100.00% |
| A145020 Stock Forecast | Hugel | Buy |
16
|
₩208.00k | Buy/Sell | ₩201.75k | 5.29% |
| A009420 Stock Forecast | Hanall Biopharma | Buy |
14
|
₩34.75k | Buy/Sell | ₩44.67k | 29.50% |
| A019170 Stock Forecast | Shinpoong Pharmaceutical Co.,L... | - |
14
|
₩12.96k | Buy/Sell | ₩0.00 | -100.00% |
Sam Chun Dang Pharm. Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Sam Chun Dang Pharm.'s Revenue has grown, increasing from ₩166.86B to ₩177.34B – a growth of 6.28%. For the next year, 0 analysts project Sam Chun Dang Pharm.'s Revenue to drop by 3.86%, reaching ₩170.48B. By 2030, professionals believe that Sam Chun Dang Pharm.'s Revenue will decrease by 3.81%, reaching ₩170.58B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A069620 Stock Forecast | Daewoong pharmaceutical Co.,Lt... | Buy |
16
|
₩112.70k | Buy/Sell | ₩156.10k | 37.53% |
| A185750 Stock Forecast | Chong Kun Dang Pharmaceutical | Outperform |
16
|
₩101.10k | Buy/Sell | ₩124.29k | 48.37% |
| A005250 Stock Forecast | Green Cross Holdings | - |
16
|
₩16.17k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A001060 Stock Forecast | JW Pharmaceutical | Buy |
14
|
₩30.40k | Buy/Sell | ₩40.62k | 38.16% |
| A003850 Stock Forecast | Boryung | Buy |
17
|
₩10.93k | Buy/Sell | ₩13.50k | 46.39% |
| A086450 Stock Forecast | DongKook Pharmaceutical | Buy |
16
|
₩16.28k | Buy/Sell | ₩20.00k | 47.42% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A003090 Stock Forecast | Daewoong | Outperform |
14
|
₩18.18k | Buy/Sell | ₩38.00k | 37.51% |
| A000640 Stock Forecast | Dong-A Socio Holdings | - |
13
|
₩110.20k | Buy/Sell | ₩0.00 | -100.00% |
| A170900 Stock Forecast | Dong-A ST | Outperform |
17
|
₩67.50k | Buy/Sell | ₩74.50k | 20.74% |
Sam Chun Dang Pharm. EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Sam Chun Dang Pharm.'s EBITDA has grown by 83.96%, rising from ₩10.99B to ₩20.22B. According to 0 major analysts, Sam Chun Dang Pharm.'s EBITDA will fall by 18.66% in the next year, reaching ₩16.45B. Professionals believe that By 2030, Sam Chun Dang Pharm.'s EBITDA will fall to ₩16.55B– a 18.16% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A058820 Stock Forecast | CMG Pharmaceutical | - |
14
|
₩2.24k | Buy/Sell | ₩0.00 | -100.00% |
| A140410 Stock Forecast | Mezzion Pharma | - |
6
|
₩36.55k | Buy/Sell | ₩0.00 | -100.00% |
| A102460 Stock Forecast | REYON Pharmaceutical | - |
15
|
₩15.75k | Buy/Sell | ₩0.00 | -100.00% |
Sam Chun Dang Pharm. EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Sam Chun Dang Pharm.'s EBIT has grown by 191.87%, rising from ₩4.31B to ₩12.57B. In the next year, 0 analysts estimate that Sam Chun Dang Pharm.'s EBIT will decrease by 105.04%, reaching ₩-633.04M. According to professional forecasts, in 2030, Sam Chun Dang Pharm.'s EBIT will decrease by 4882.33%, reaching ₩-601.08B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A047920 Stock Forecast | HLB Pharmaceutical | - |
4
|
₩34.90k | Buy/Sell | ₩0.00 | -100.00% |
| A007570 Stock Forecast | Ilyang Pharmaceutical Co.,Ltd | - |
13
|
₩14.56k | Buy/Sell | ₩0.00 | -100.00% |
| A003000 Stock Forecast | Bukwang Pharmaceutical | - |
10
|
₩6.15k | Buy/Sell | ₩17.66k | -100.00% |
Sam Chun Dang Pharm. EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Sam Chun Dang Pharm.'s EPS has grown, increasing from ₩-45.00 to ₩0.00 – a growth of 100.00%. The next year looks promising for Sam Chun Dang Pharm., with analysts predicting EPS of ₩0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Sam Chun Dang Pharm.'s EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A053030 Stock Forecast | BINEX | - |
16
|
₩13.49k | Buy/Sell | ₩18.00k | -59.12% |
| A249420 Stock Forecast | Ildong Pharmaceutical | Outperform |
12
|
₩15.28k | Buy/Sell | ₩23.00k | 63.61% |
| A243070 Stock Forecast | Huons | Outperform |
18
|
₩34.35k | Buy/Sell | ₩45.00k | 57.21% |
.jpg)